CrossrefInfokarte
Subcutaneous Trastuzumab (Herceptin<sup>®</sup>): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer
Advances in Breast Cancer Research · 2013 · 02 (04) · 133-140
DOI: 10.4236/abcr.2013.24022 ↗Abstract
Kein Abstract verfügbar.
EUVIMED